

CooperCompanies

Fiscal 2023 financial guidance

		FY23 Guidance*	Organic Growth vs. FY22
Sales	Total	\$3,455 - \$3,515	6% - 8%
	CooperVision	\$2,325 - \$2,365	7% - 9%
	CooperSurgical	\$1,130 - \$1,150	4% - 6%
EPS	Non-GAAP	\$12.30 - \$12.60	



CooperCompanies

Note: Sales \$ in millions; Organic growth excludes the effect of foreign currency fluctuations, and excluding the impact of any acquisitions, divestitures, discontinuations that occurred in the comparable period.
Non-GAAP and organic – a reconciliation of these measures are available under the "Reconciliation of Selected GAAP Results to Non-GAAP Results" section in our earning releases and under the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on the Company's website: www.coopercos.com.

*Guidance initiated 12/8/22. FY23 financial guidance does not include the Cook Medical Reproductive Health acquisition announced on 2/7/22 as the transaction is pending regulatory approval.